Trial · NCT04218968
Cardiac Changes in Early Parkinson's Disease: A Follow up Study
NCT04218968, Phase 2, Active not recruiting, Cedars-Sinai Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cardiac Changes in Early Parkinson's Disease: A Follow up Study. Trials, record NCT04218968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04218968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cardiac Changes in Early Parkinson's Disease: A Follow up Study
- NCT number
- NCT04218968
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Cedars-Sinai Medical Center
- Conditions
- REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
- Interventions
- Carvedilol
- First posted
- 2020-01-06
- Last updated
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in 123I-Ioflupane uptake - DATscan | Every year for three years | Changes in 123I-Ioflupane uptake, as measured by specific binding ratio (SBR), between baseline, year one, year two and year three. |
| Secondary | Diagnosis of PD or other synucleinopathies by the end of 3 years in the study population | Every year for 3 years | Clinical evaluation |
| Secondary | Changes in 123I-MIBG late H/M | Every 6 months for 3 years | Changes in 123I-MIBG reuptake, as measured by late H/M ratio, between baseline and every six months for three years |
| Secondary | Changes in 123I-MIBG WR rate | Every 6 months for 3 years | Changes in 123I-MIBG WR reuptake, as measured by WR rate, between baseline and every six months for three years |
| Secondary | Sensitivity and specificity of DAT Scan compared to MIBG in predicting RBD conversion to PD/other synucleinopathies | Every year for3 years | Changes in 123I-Ioflupane uptake, as measured by specific binding ratio (SBR), between baseline, year one, year two and year three. |
| Other | MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III | Every 6 months for 3 years | MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III changes from OFF medication between baseline and every 6 months for three years |
| Other | Non-Motor Symptoms Scale (NMSS) changes | Every 6 months for 3 years | Non-Motor Symptoms Scale (NMSS) changes between baseline and every 6 months for three years |
| Other | Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) | Every 6 months for 3 years | Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) changes between baseline and every 6 months for three years |
| Other | REM sleep Behavior Disorder Screening questionnaire (RBDSQ) | Every 6 months for 3 years | REM sleep Behavior Disorder Screening questionnaire (RBDSQ) changes between baseline and every 6 months for three years |
| Other | University of Pennsylvania Smell Identification Test (UPSIT) | Every 6 months for 3 years | University of Pennsylvania Smell Identification Test (UPSIT) changes between baseline and every 6 months for three years |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04218968
GET https://conductscience.org/api/trials/v1/NCT04218968/registered